305 related articles for article (PubMed ID: 35809408)
1. In silico and in vitro analysis of PPAR - α / γ dual agonists: Comparative evaluation of potential phytochemicals with anti-obesity drug orlistat.
Mandal SK; Kumar BK; Sharma PK; Murugesan S; Deepa PR
Comput Biol Med; 2022 Aug; 147():105796. PubMed ID: 35809408
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of phytocannabinoids as novel dual PPARα/γ agonists by a computational and in vitro experimental approach.
D'Aniello E; Fellous T; Iannotti FA; Gentile A; Allarà M; Balestrieri F; Gray R; Amodeo P; Vitale RM; Di Marzo V
Biochim Biophys Acta Gen Subj; 2019 Mar; 1863(3):586-597. PubMed ID: 30611848
[TBL] [Abstract][Full Text] [Related]
3. Computational investigation of phytochemicals from
Omoboyowa DA; Singh G; Fatoki JO; Oyeneyin OE
J Biomol Struct Dyn; 2023; 41(12):5568-5582. PubMed ID: 35773777
[TBL] [Abstract][Full Text] [Related]
4. Identification of phytochemicals as putative ligands for the targeted modulation of peroxisome proliferator-activated receptor α (PPARα) in animals.
Hassan FU; Rehman MS; Javed M; Ahmad K; Fatima I; Safdar M; Ashraf N; Nadeem A
J Biomol Struct Dyn; 2023 Oct; ():1-12. PubMed ID: 37837423
[TBL] [Abstract][Full Text] [Related]
5. Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?
Gani OA
Cardiovasc Diabetol; 2008 Mar; 7():6. PubMed ID: 18355413
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel PPARα/γ dual agonists by virtual screening, ADMET prediction and molecular dynamics simulations.
Liu X; Jing Z; Jia WQ; Wang SQ; Ma Y; Xu WR; Liu JW; Cheng XC
J Biomol Struct Dyn; 2018 Aug; 36(11):2988-3002. PubMed ID: 28853334
[TBL] [Abstract][Full Text] [Related]
7. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
[TBL] [Abstract][Full Text] [Related]
8. The natural compounds, Magnolol or Honokiol, promote adipose tissue browning and resist obesity through modulating PPARα/γ activity.
Chu Y; Gui S; Zheng Y; Zhao J; Zhao Y; Li Y; Chen X
Eur J Pharmacol; 2024 Apr; 969():176438. PubMed ID: 38402928
[TBL] [Abstract][Full Text] [Related]
9. Antiobesity drug-likeness properties and pancreatic lipase inhibition of a novel low molecular weight lutein oxidized product, LOP6.
Shamarao N; Chethankumar M
Food Funct; 2022 Jun; 13(11):6036-6055. PubMed ID: 35615990
[TBL] [Abstract][Full Text] [Related]
10.
Feng XY; Ding TT; Liu YY; Xu WR; Cheng XC
J Biomol Struct Dyn; 2021 Mar; 39(5):1853-1864. PubMed ID: 32189570
[TBL] [Abstract][Full Text] [Related]
11. Scaffold-based pan-agonist design for the PPARα, PPARβ and PPARγ receptors.
Zhang LS; Wang SQ; Xu WR; Wang RL; Wang JF
PLoS One; 2012; 7(10):e48453. PubMed ID: 23119024
[TBL] [Abstract][Full Text] [Related]
12. Exploring Dual Agonists for PPARα/γ Receptors using Pharmacophore Modeling, Docking Analysis and Molecule Dynamics Simulation.
Ding TT; Liu YY; Zhang LM; Shi JR; Xu WR; Li SY; Cheng XC
Comb Chem High Throughput Screen; 2022; 25(9):1450-1461. PubMed ID: 34182904
[TBL] [Abstract][Full Text] [Related]
13. The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD.
Dixon ED; Nardo AD; Claudel T; Trauner M
Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33926085
[TBL] [Abstract][Full Text] [Related]
14. Molecular dynamics articulated multilevel virtual screening protocol to discover novel dual PPAR α/γ agonists for anti-diabetic and metabolic applications.
Mandal S; Faizan S; Raghavendra NM; Kumar BRP
Mol Divers; 2023 Dec; 27(6):2605-2631. PubMed ID: 36437421
[TBL] [Abstract][Full Text] [Related]
15. Probing intermolecular interactions and binding stability of kaempferol, quercetin and resveratrol derivatives with PPAR-γ: docking, molecular dynamics and MM/GBSA approach to reveal potent PPAR- γ agonist against cancer.
Lokhande KB; Ballav S; Yadav RS; Swamy KV; Basu S
J Biomol Struct Dyn; 2022 Feb; 40(3):971-981. PubMed ID: 32954977
[TBL] [Abstract][Full Text] [Related]
16. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M
J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380
[TBL] [Abstract][Full Text] [Related]
17. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.
Evans JL; Lin JJ; Goldfine ID
Curr Diabetes Rev; 2005 Aug; 1(3):299-307. PubMed ID: 18220606
[TBL] [Abstract][Full Text] [Related]
18. Exploring conformational changes of PPAR-Ɣ complexed with novel kaempferol, quercetin, and resveratrol derivatives to understand binding mode assessment: a small-molecule checkmate to cancer therapy.
Lokhande KB; Ballav S; Thosar N; Swamy KV; Basu S
J Mol Model; 2020 Aug; 26(9):242. PubMed ID: 32816149
[TBL] [Abstract][Full Text] [Related]
19. Exploring binding mode assessment of novel kaempferol, resveratrol, and quercetin derivatives with PPAR-α as potent drug candidates against cancer.
Ballav S; Lokhande KB; Yadav RS; Ghosh P; Swamy KV; Basu S
Mol Divers; 2023 Dec; 27(6):2867-2885. PubMed ID: 36544031
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) as a Target for Concurrent Management of Diabetes and Obesity-Related Cancer.
Wang Q; Imam MU; Yida Z; Wang F
Curr Pharm Des; 2017; 23(25):3677-3688. PubMed ID: 28677503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
